NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Vistagen Therapeutics, Inc. VTGN
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.3M
▲ 161.1% vs FY2024
EPS · FY25
$-1.83
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-131.6%
Net margin · FY25
-5491.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.3M
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 5491 cents on every revenue dollar this year.
Per share
USD -1.83
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-131.6%
Return on equity, FY2025
ROE
Operating margin-5683.7%
Net margin-5491.3%
Return on assets-104.9%
Each USD of equity lost 132 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+3.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+3.1%
−3.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 48.6M
total assets, end of FY2025
Total assetsUSD 48.6M
EquityUSD 35.5M
CashUSD 30.8M
Gross debtUSD 96,000.00
Net debtUSD -30.7M
Current ratio3.67×
The company holds more cash than debt.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
·
0.0
0.0
0.0
·
·
0.0
0.0
0.0
·
·
·
Operating income $B
−0.1
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
EBITDA $B
−0.1
−0.1
−0.0
−0.1
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
Net income $B
−0.1
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.83
−1.67
−1.52
−8.51
·
−0.49
−0.50
−0.90
−1.12
−1.54
−29.08
−10.61
−3.81
−1.27
−0.83
−1.81
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−131.6
−55.7
−46.5
−154.3
−61.0
−41.6
−3087.2
−351.5
−380.9
·
·
·
·
·
·
·
·
·
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed